Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: London
  • Sector: Health Care
  • Industry: Health Care Facilities & Svcs
  • Sub-Industry: Health Care Services

INS:LN

209.000 GBp 0.0000.00%

As of 11:35:01 ET on 06/02/2015.

Snapshot for Instem PLC (INS)

Open: 209.000 Day's Range: 209.000 - 209.000 Volume: 1,000
Previous Close: 209.000 52wk Range: 123.500 - 212.500 1-Yr Rtn: +14.52%

Stock Chart for INS

No chart data available.
  • INS:LN 209.000
  • 1D
  • 1M
  • 1Y
209.000
Interactive INS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for INS

Current P/E Ratio (ttm) 174.1667
Estimated P/E(12/2015) 20.0962
Relative P/E vs. UKX 7.9924
Earnings Per Share (GBP) (ttm) 0.0120
Est. EPS (GBP) (12/2015) 0.1040
Est. PEG Ratio -
Market Cap (M GBP) 25.52
Shares Outstanding (M) 12.21
30 Day Average Volume 8,733
Price/Book (mrq) 4.7100
Price/Sale (ttm) 1.8798
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 09/24/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for INS

  • Revenue
  • Net Income (M/GBP)
  • Profit Margin (%)

Company Profile & Key Executives for INS

Instem PLC provides information technology applications to the global early development healthcare market. The Group is focused on the early development sector of the drug and chemical research and development industry, from late discovery and lead optimisation through to the Phase I clinical evaluation stage.

Philip John Reason "Phil"Chief Executive OfficerNigel J GoldsmithCFO/Secretary
More Company Profile & Key Executives for INS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil